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tients will have a large impact on drug expenditures. As the
price of thiotepa continues to rise and alternative regimens
are utilized more frequently, there remains a responsibility
for the practitioner to report and determine the most effec-
tive, safe, and economically responsible pediatric hemato-
poietic stem cell transplant conditioning regimen.Figure 1.542
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Background: Tacrolimus (TAC) remains the backbone of
graft-versus-host disease (GVHD) prophylaxis in allogeneic
hematopoietic stem cell transplantation (HSCT). There is
signiﬁcant variability in the serum concentrations of TAC
attained early post-transplant due to drug interactions
and genomic variation. Whether a relationship exists
between early TAC concentrations and acute GVHD in
reduced-intensity conditioning (RIC) HSCT remains poorly
characterized.
Methods: We aimed to retrospectively evaluate whether
mean weekly TAC concentrations correlate with incidence of
acute GVHD in 120 consecutive patients (pts) undergoing
ﬁrst allogeneic HSCT at the University of Pennsylvania be-
tween January 2009 and January 2014. All pts received a
uniform RIC regimen of ﬂudarabine (120 mg/m2) and
busulfan (6.4 mg/kg), followed by infusion of peripheral-
blood stem cells from either a related (n¼53) or unrelated
(n¼67) donor. All pts received standard GVHD prophylaxis
with oral TAC (0.06 mg/kg/day) beginning day -3 and intra-
venous methotrexate (15 mg/m2 day +1, 10 mg/m2 days +3,
+6, +11). The dose of TAC was adjusted to a target trough of
5e15 ng/mL. The primary endpoint was the incidence of
acute grade 2e4 GVHD. We analyzed mean weekly TAC
concentrations as continuous variables up to 4 weeks post-
HSCT and then classiﬁed pts in tertiles (e.g., week 1: 8.5,
8.5e12;>12 ng/mL). Univariate analyses were performed
using cumulative incidence and Cox regression models.
Multivariate models were constructed using the backward
elimination method.
Results: The mean TAC concentrations (ranges) at 1, 2, 3, and
4 weeks after RIC HSCT were 10.2 (2.8e19.4), 10.6 (3.9e23.9),
12.7 (4.2e24.1), and 11.9 (2.9e29.2) ng/mL, respectively. The
day-180 cumulative incidence of acute grade 2e4 GVHD was
42.5%. In multivariate analysis, week 1 TAC concentration
was an independent predictor of acute grade 2e4 GVHD (HR
0.91; 0.84e0.97; P¼.008). Interestingly, this association was
driven by a lower risk of acute grade 2e4 GVHD in pts with
week 1 TAC concentrations in the upper tertile (>12 ng/mL)(HR 0.47; 0.25e0.88; P¼.02), as shown in Figure 1. Week 1
TAC concentrations were not predictive of relapse, chronic
GVHD, overall survival or non-relapse mortality. In this
cohort, 9 pts (7.5%) developed acute kidney injury (AKI) by
day 14. Week 1 TAC concentrations were higher in pts who
developed AKI compared to those who did not (13.0 vs. 10.0
ng/mL; P¼.01). We did not observe an association between
TAC concentrations at weeks 2, 3, and 4 and clinical
outcomes.
Conclusion: Higher TAC concentrations during the ﬁrst
week after RIC HSCT were associated with signiﬁcantly
reduced risk of acute grade 2e4 GVHD without increasing
risk of relapse. These data highlight the importance of opti-
mizing initial dosing of TAC in RIC HSCT recipients.543
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Background: Optimal dosing andmonitoring of MMF and its
metabolites has been a subject of extensive debate/in-
vestigations in the stem cell transplant literature. Due to a
shorter half-life and lack of enterohepatic recycling, more
frequent and higher dosing of MMF may be required in the
early post-AlloSCT period, particularly in children. [Bhatia/
Cairo et al. BBMT 2010;16(3):333-43.]
